Baylor College of Medicine The Dan L. Duncan Comprehensive Cancer Center | Strategic Alliance Partners

August 29, 2018

Matthew J. Ellis, MD, PhD, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

August 22, 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular testing in gastrointestinal cancers.

August 21, 2018

Scott Paulson, MD, discusses recent updates in the treatment of patients with neuroendocrine tumors.

August 21, 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera (lutetium Lu 177 dotatate) in patients with neuroendocrine tumors (NETs).

August 21, 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

August 31, 2017

Supported by research, there have been recent developments in using scalp cooling to combat chemotherapy-induced alopecia for patients with breast cancer.

May 29, 2013

Some HER2-positive breast cancer patients may be able to receive targeted neoadjuvant therapy with lapatinib and trastuzumab without chemotherapy.